https://www.bioworld.com/rss en-us New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria. http://www.bioworld.com/articles/733043 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733043-apac-roundup-nmpa-nods-lupins-16m-spinoff-car-t-data-more Globe isolated on white background with focus on Asia and Australia Suggesting Replimune Group Inc.’s statistical analysis method inflated responses in the single-arm phase II Ignyte trial of RP-1 (suvolimogene oderparepvec), briefing documents ahead of the U.S. FDA’s Cellular, Tissue, and Gene Therapies advisory committee meeting on July 30 sent the company’s shares spiraling downward by about 38%. http://www.bioworld.com/articles/732927 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732927-replimunes-rollercoaster-fda-adcom-signals-another-bumpy-ride Path shaped like a fluctuating arrow graph Shanghai Jeyou Pharmaceutical Co. Ltd. has discovered new ATP-dependent RNA helicase A (DHX9) inhibitors potentially useful for the treatment of cancer, viral infection and autoimmune disease. http://www.bioworld.com/articles/732991 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732991-shanghai-jeyou-pharmaceutical-identifies-new-dhx9-inhibitors Shanghai Escugen Biotechnology Co. Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic drug potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732990 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732990-shanghai-escugen-biotechnology-reports-new-trop2-targeting-adcs Promatix Biosciences Ltd. has been awarded an Innovate UK Biomedical Catalyst grant to support development of its lead program, PBS-293-exatecan, a first-in-class EGFR x EphA2 cis-bispecific antibody-drug conjugate. http://www.bioworld.com/articles/732979 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732979-promatix-advances-pbs-293-exatecan-with-innovate-uk-grant Colon cancer illustration Exeliris Co. Ltd. and Lin Gang Laboratory have reported phosphatidylinositol 3-kinase α (PI3Kα) inhibitors that are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732971 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732971-exeliris-and-lin-gang-laboratory-identify-new-pi3k-inhibitors Fortvita Biologics Inc. and Innovent Biologics (Hangzhou) Co. Ltd. have patented bispecific antibody-drug conjugates (ADCs) comprising a bispecific humanized monoclonal antibody targeting EGFR and hepatocyte growth factor receptors (HGFR; MET) linked to cytotoxic drugs reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732970 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732970-fortvita-biologics-and-innovent-biologics-disclose-new-bispecific-adcs-targeting-egfr-and-hgfr Betta Pharmaceuticals Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds consisting of a Von Hippel-Lindau-binding moiety coupled to a GTPase KRAS-targeting moiety through a linker acting as KRAS degradation inducers. http://www.bioworld.com/articles/732967 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732967-betta-pharmaceuticals-reports-new-kras-degradation-inducers Veraxa Biotech AG has reported the advancement of its bispecific antibody-drug conjugate (bsADC) program VXA-222, following achievement of a technical milestone in its alliance with Omniab Inc. The program is moving into its next collaboration phase. http://www.bioworld.com/articles/732960 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732960-veraxa-biotech-advances-bispecific-adc-from-omniab-collaboration 3D rendering of a drug capsule and flying antibodies Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. said its IND application was approved in China for SKB-565, its dual-payload antibody-drug conjugate (ADC), for the treatment of advanced solid tumors. http://www.bioworld.com/articles/732959 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732959-kelun-biotechs-skb-565-cleared-to-enter-clinic-in-china Antibody-drug conjugate illustration At the American Association for Cancer Research’s inaugural Drug Discovery and Development conference (AACR D3), Onconano Medicine Inc. presented preclinical data on ONM-421, a pH-responsive polymer-drug conjugate nanoparticle developed using the company’s proprietary ON-BOARD platform. http://www.bioworld.com/articles/732957 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732957-aacr-d3-onm-421-shows-antigen-independent-tumor-control 3D representation of tumor Researchers from the Ocean University of China described XZ-8078, a new dual-target protein degrader that simultaneously targets PARP1 and IKZF3, offering a potential strategy to enhance antitumor activity through coordinated pathway inhibition. http://www.bioworld.com/articles/732956 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732956-dual-parp1-ikzf3-degrader-overcomes-parp-inhibitor-resistance New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria. http://www.bioworld.com/articles/732867 Fri, 24 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732867-apac-roundup-nmpa-nods-lupins-16m-spinoff-car-t-data-more Globe isolated on white background with focus on Asia and Australia Bioray Pharmaceutical Co. Ltd. has prepared and tested new antibody-drug conjugates consisting of antibodies covalently linked to payloads. They are reported to be potentially useful for the treatment of cancer, infections, inflammatory and immunological disorders. http://www.bioworld.com/articles/732910 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732910-antibody-drug-conjugates-reported-in-bioray-pharmaceutical-patent Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer. http://www.bioworld.com/articles/732908 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732908-hengrui-synthesizes-new-adcs-targeting-ceacam5 Zonsen Peplib Biotech Inc. has synthesized new peptide-drug conjugates comprising a glypican-3 (GPC3)-targeting peptide covalently linked to a payload potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732907 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732907-zonsen-peplib-biotech-discloses-new-gpc3-targeting-peptide-drug-conjugates A recent Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. patent describes new 4-substituted fused bicyclic heteroaryl derivatives acting as Kelch-like ECH-associated protein 1 (Keap1)/CUL3 interaction inducers reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732906 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732906-beone-patents-new-keap1-cul3-interaction-inducers Sprint Bioscience AB has entered into an agreement to use Lilly Tunelab, Eli Lilly and Co.’s AI-based drug discovery platform, to support work on its research portfolio. http://www.bioworld.com/articles/732901 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732901-sprint-bioscience-to-use-lilly-tunelab-in-drug-development Pill over molecule structures HCW Biologics Inc. has requested a type B (pre-IND) meeting with the FDA to discuss the development and regulatory strategy for its investigational tetravalent T-cell engager (TCE), HCW-11-018b, for solid tumors. http://www.bioworld.com/articles/732898 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732898-hcw-biologics-seeks-pre-ind-meeting-with-fda-for-hcw-11-018b 3D illustration of T cells fighting cancer Thyora Therapeutics has launched with a mission to leverage next-generation covalent chemistry to accelerate clinical translation and create therapies for unmet medical needs. http://www.bioworld.com/articles/732896 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732896-new-thyora-therapeutics-focuses-on-covalent-drug-discovery Doctor hand touching virtual molecular structure Shenzhen Targetrx Inc. has patented proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to a hepatocyte growth factor receptor (HGFR, MET)-targeting moiety via linker acting as HGFR degradation inducers potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732890 Thu, 23 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732890-shenzhen-targetrx-discloses-new-hgfr-degradation-inducers Shanghai Escugen Biotechnology Co. Ltd. has disclosed new antibody-drug conjugates comprising chimeric monoclonal antibodies targeting CD174 (Lewis y) covalently linked to a cytotoxic drug. They are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732889 Thu, 23 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732889-shanghai-escugen-biotechnology-patents-adcs-targeting-cd174 Tikva Allocell Pte. Ltd. has closed an $8 million series A financing to support its development of engineered, allogeneic cell therapies for adult and pediatric patients with solid tumors. http://www.bioworld.com/articles/732882 Thu, 23 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732882-series-a-financing-at-tikva-allocell-to-advance-tavst-01 CAR T cell attacking cancer cells Illustration of CAR T cell attacking cancer cells. Credit: La Jolla Institute About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in non-small-cell lung cancer (NSCLC). Branded Jideytro, the ROS1 selective inhibitor is indicated for use in adults with locally advanced or metastatic ROS1-positive disease who have received a prior ROS1 kinase inhibitor. http://www.bioworld.com/articles/732912 Wed, 22 Jul 2026 17:11:35 -0400 https://www.bioworld.com/articles/732912-gsks-newly-acquired-jideytro-wins-fda-nod-in-nsclc Lung cancer illustration Haisco Pharmaceutical Group Co. Ltd. has identified compounds acting as signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders. http://www.bioworld.com/articles/732833 Wed, 22 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732833-haisco-pharmaceutical-reports-new-stat6-inhibitors Verismo Therapeutics Inc. has reported a new preclinical KIR-CAR program targeting the Claudin 6 (CLDN6) antigen to treat CLDN6-expressing solid tumors. The program is built around a CLDN6-directed binder discovered at the University of Pennsylvania Perelman School of Medicine through a Verismo-sponsored research agreement. http://www.bioworld.com/articles/732824 Wed, 22 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732824-verismo-unveils-cldn6-targeting-kir-car-program Dividing cancer cells in the cross hairs In breast cancer, dysregulated Hippo signaling results in activation of the YAP/TAZ-TEAD transcriptional complex, which induces a broad oncogenic transcriptional program. This gene expression network promotes tumor cell proliferation, survival, invasion and metastatic dissemination, while also contributing to resistance to anticancer therapies. Researchers from Harbin Medical University reported the preclinical characterization of M-511-0965, a YAP-TEAD4 inhibitor, in models of triple-negative breast cancer (TNBC). http://www.bioworld.com/articles/732822 Wed, 22 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732822-m-511-0965-blocks-yap-tead4-signaling-in-tnbc Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd. and its EGFR inhibitor for lung cancer, as well as Innovent Biologics Inc. and its anti-CD40L antibody for a chronic fibroinflammatory condition. http://www.bioworld.com/articles/732844 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732844-asia-deal-flurry-draws-az-spero-to-1b-dizal-innovent-assets Global deals illustration Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization. http://www.bioworld.com/articles/732842 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732842-capital-remains-selective-in-barbell-biotech-market International currency symbols Advancell Co. Ltd. has raised an oversubscribed $315 million series D round to accelerate its push to become a fully integrated global radiopharma developer, funding late-stage clinical development alongside isotope supply and manufacturing infrastructure. http://www.bioworld.com/articles/732841 Tue, 21 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732841-advancell-raises-315m-to-power-global-isotope-strategy Philina Lee, CEO, Advancell Advancell CEO Philina Lee (left). Credit: Advancell Co. Ltd.